We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Kronos Worldwide, Kraton, Ingevity, W. R. Grace and Arkema S.A.
Read MoreHide Full Article
For Immediate Release
Chicago, IL – Dec 21, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Kronos Worldwide, Inc.(KRO - Free Report) , Kraton Corporation , Ingevity Corporation (NGVT - Free Report) , W. R. Grace & Co. and Arkema S.A. (ARKAY - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
5 Chemical Growth Stocks to Revitalize Your Portfolio
The chemical industry has gotten its mojo back after being roiled by the global economic crisis. The industry enjoyed a positive run this year, helped by an upswing in the world economy and strength across major end-use markets such as construction, electronics and automotive.
The Zacks Chemicals Diversified industry has outperformed the broader market year to date. The industry has gained around 26.6% over this period, topping S&P 500’s corresponding return of roughly 20.6%.
U.S. Chemical Industry to Ride Growth Wave
The U.S. Chemical Industry has recovered from the damaging effects of Hurricane Harvey and is set for solid growth in 2018. The American Chemistry Council (ACC), an industry trade group, envisions national chemical production (excluding pharmaceuticals) to rise 3.7% in 2018, further accelerating to a 3.9% growth in 2019. The growth is expected to be spurred by higher demand across light vehicles and housing markets, capital investments and improved export markets.
The trade group also expects basic chemicals production to expand 4.7% in 2018 and further gain steam with a 5.2% rise in 2019 on the heels of new capacity additions. Major export markets such as Latin America and Asia are expected to play a significant role in production growth.
The United States remains an attractive investment destination for chemical investment and domestic chemical makers continue to enjoy the advantage of access to abundant and cheaper feedstocks and energy. This is driving investment in chemical production projects.
Per the ACC, roughly 320 chemical projects have been already announced worth more than $185 billion, 62% of which is foreign direct investment. Moreover, roughly 65% of the chemical investment announced since 2010 are complete or under construction. New capacity is expected to provide a boost to chemical production as these investments come on stream.
The ACC also expects chemical industry capital spending to rise 6.3% in 2018 and 6.8% in 2019 and eventually reach $48 billion by 2022.
EU Chemical Sector Back in Business
The European chemical industry has also swung back to life on the back of improving global economic sentiment and a resurgent Eurozone economy. Eurozone’s recovery has been backed by declining unemployment and strengthening business and consumer confidence.
The outlook for the European chemical industry is positive. The European Chemical Industry Council (CEFIC) expects chemical output in the European Union to rise 2% year over year in 2018. Per the CEFIC, the growth of manufacturing production across sectors such as automotive, construction, metal production and electronics in the European Union has led to higher demand for chemicals in the region. Exports of chemicals produced in European Union have also increased, particularly, in Asia and Russia.
Demand Strength Across Key End-Markets
Chemical makers continue to see strong demand from construction and automotive sectors – major chemical end-use markets. A recovery across housing and commercial construction markets has been a tailwind for the chemical industry. The underlying trends in the housing space remain healthy, backed by steady buyer demand, low mortgage rates, high homebuilders’ confidence, low unemployment levels and rising rent costs.
The automotive sector also continues its good run amid certain challenges, supported by an improving job market, rising personal income, improved consumer confidence, low fuel prices, impressive vehicle launches and attractive financing options.
Another positive is a recovery in demand in the energy space – a key chemical end-market that had been out of favor for a while. The recovery has been driven by the rebound in crude oil prices. The recent uptrend in oil prices has been supported by a decline in U.S. oil stockpiles and extension of oil production cuts by OPEC and other major world producers until the end of 2018. Improving fundamentals in the energy space is expected to support chemical demand next year.
5 Chemical Growth Plays
The chemical industry is looking up, making it an attractive investment proposition for 2018. The industry’s momentum is expected to continue next year on sustained demand strength across major end-markets and significant capital investment. Amid such a backdrop, it would be a prudent idea to invest in chemical stocks with compelling growth prospects if you are looking to reap solid returns from your portfolio in 2018.
Growth investors look for stocks with aggressive earnings or revenue growth potential, which should lead to higher stock prices. With the help of our Style Score System, we have picked five stand-out chemical stocks that have excellent prospects and might offer solid investment returns.
Our research shows that stocks with Growth Style Score of A or B when combined with Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy) offer the best investment opportunities in the growth investing space. You can see the complete list of today’s Zacks #1 Rank stocks here.
Kronos Worldwide, Inc.
Headquartered in Dallas, TX, Kronos sports a Zacks Rank #1 and a Growth Score of A. The company has expected earnings growth of 41.1% for 2018. It delivered average positive earnings surprise of 58.8% over the trailing four quarters. Kronos also has a long-term expected earnings per share (EPS) growth rate of 5%. (Looking for the Best Stocks for 2018? Be among the first to see our Top Ten Stocks for 2018 portfolio here.)
Kraton Corporation
Our next pick in the space is Texas-based Kraton, armed with a Zacks Rank #1 and a Growth Score of A. The company has an expected EPS growth of 30.6% for 2018. It also delivered average positive earnings surprise of 32.9% over the trailing four quarters. Earnings estimates for 2018 for the company have also increased by around 10% over the last 60 days.
Ingevity Corporation
South Carolina-based Ingevity is another attractive choice with a Zacks Rank #2 and a Growth Score A. The company has expected earnings growth of 14.3% for 2018. The company also delivered positive earnings surprise in each of the trailing four quarters with an average positive surprise of 10.4%. The stock has a long-term expected EPS growth rate of 12%.
W. R. Grace & Co.
Headquartered in Columbia, MD, W. R. Grace carries a Zacks Rank #2 and Growth Score A. The company has expected earnings growth of 8.5% for 2018. It also delivered positive earnings surprise in each of the trailing four quarters with an average positive surprise of 6.3%. Its long-term projected EPS growth rate is 12%.
Arkema S.A.
France-based Arkema sports a Zacks Rank #2 and a Growth Score of A. The company has expected earnings growth of 8.3% for 2018. The Zacks Consensus Estimate for 2018 for the company have increased by around 1% over the last 60 days. Arkema also has a long-term expected EPS growth rate of 13.1%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Kronos Worldwide, Kraton, Ingevity, W. R. Grace and Arkema S.A.
For Immediate Release
Chicago, IL – Dec 21, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Kronos Worldwide, Inc.(KRO - Free Report) , Kraton Corporation , Ingevity Corporation (NGVT - Free Report) , W. R. Grace & Co. and Arkema S.A. (ARKAY - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
5 Chemical Growth Stocks to Revitalize Your Portfolio
The chemical industry has gotten its mojo back after being roiled by the global economic crisis. The industry enjoyed a positive run this year, helped by an upswing in the world economy and strength across major end-use markets such as construction, electronics and automotive.
The Zacks Chemicals Diversified industry has outperformed the broader market year to date. The industry has gained around 26.6% over this period, topping S&P 500’s corresponding return of roughly 20.6%.
U.S. Chemical Industry to Ride Growth Wave
The U.S. Chemical Industry has recovered from the damaging effects of Hurricane Harvey and is set for solid growth in 2018. The American Chemistry Council (ACC), an industry trade group, envisions national chemical production (excluding pharmaceuticals) to rise 3.7% in 2018, further accelerating to a 3.9% growth in 2019. The growth is expected to be spurred by higher demand across light vehicles and housing markets, capital investments and improved export markets.
The trade group also expects basic chemicals production to expand 4.7% in 2018 and further gain steam with a 5.2% rise in 2019 on the heels of new capacity additions. Major export markets such as Latin America and Asia are expected to play a significant role in production growth.
The United States remains an attractive investment destination for chemical investment and domestic chemical makers continue to enjoy the advantage of access to abundant and cheaper feedstocks and energy. This is driving investment in chemical production projects.
Per the ACC, roughly 320 chemical projects have been already announced worth more than $185 billion, 62% of which is foreign direct investment. Moreover, roughly 65% of the chemical investment announced since 2010 are complete or under construction. New capacity is expected to provide a boost to chemical production as these investments come on stream.
The ACC also expects chemical industry capital spending to rise 6.3% in 2018 and 6.8% in 2019 and eventually reach $48 billion by 2022.
EU Chemical Sector Back in Business
The European chemical industry has also swung back to life on the back of improving global economic sentiment and a resurgent Eurozone economy. Eurozone’s recovery has been backed by declining unemployment and strengthening business and consumer confidence.
The outlook for the European chemical industry is positive. The European Chemical Industry Council (CEFIC) expects chemical output in the European Union to rise 2% year over year in 2018. Per the CEFIC, the growth of manufacturing production across sectors such as automotive, construction, metal production and electronics in the European Union has led to higher demand for chemicals in the region. Exports of chemicals produced in European Union have also increased, particularly, in Asia and Russia.
Demand Strength Across Key End-Markets
Chemical makers continue to see strong demand from construction and automotive sectors – major chemical end-use markets. A recovery across housing and commercial construction markets has been a tailwind for the chemical industry. The underlying trends in the housing space remain healthy, backed by steady buyer demand, low mortgage rates, high homebuilders’ confidence, low unemployment levels and rising rent costs.
The automotive sector also continues its good run amid certain challenges, supported by an improving job market, rising personal income, improved consumer confidence, low fuel prices, impressive vehicle launches and attractive financing options.
Another positive is a recovery in demand in the energy space – a key chemical end-market that had been out of favor for a while. The recovery has been driven by the rebound in crude oil prices. The recent uptrend in oil prices has been supported by a decline in U.S. oil stockpiles and extension of oil production cuts by OPEC and other major world producers until the end of 2018. Improving fundamentals in the energy space is expected to support chemical demand next year.
5 Chemical Growth Plays
The chemical industry is looking up, making it an attractive investment proposition for 2018. The industry’s momentum is expected to continue next year on sustained demand strength across major end-markets and significant capital investment. Amid such a backdrop, it would be a prudent idea to invest in chemical stocks with compelling growth prospects if you are looking to reap solid returns from your portfolio in 2018.
Growth investors look for stocks with aggressive earnings or revenue growth potential, which should lead to higher stock prices. With the help of our Style Score System, we have picked five stand-out chemical stocks that have excellent prospects and might offer solid investment returns.
Our research shows that stocks with Growth Style Score of A or B when combined with Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy) offer the best investment opportunities in the growth investing space. You can see the complete list of today’s Zacks #1 Rank stocks here.
Kronos Worldwide, Inc.
Headquartered in Dallas, TX, Kronos sports a Zacks Rank #1 and a Growth Score of A. The company has expected earnings growth of 41.1% for 2018. It delivered average positive earnings surprise of 58.8% over the trailing four quarters. Kronos also has a long-term expected earnings per share (EPS) growth rate of 5%. (Looking for the Best Stocks for 2018? Be among the first to see our Top Ten Stocks for 2018 portfolio here.)
Kraton Corporation
Our next pick in the space is Texas-based Kraton, armed with a Zacks Rank #1 and a Growth Score of A. The company has an expected EPS growth of 30.6% for 2018. It also delivered average positive earnings surprise of 32.9% over the trailing four quarters. Earnings estimates for 2018 for the company have also increased by around 10% over the last 60 days.
Ingevity Corporation
South Carolina-based Ingevity is another attractive choice with a Zacks Rank #2 and a Growth Score A. The company has expected earnings growth of 14.3% for 2018. The company also delivered positive earnings surprise in each of the trailing four quarters with an average positive surprise of 10.4%. The stock has a long-term expected EPS growth rate of 12%.
W. R. Grace & Co.
Headquartered in Columbia, MD, W. R. Grace carries a Zacks Rank #2 and Growth Score A. The company has expected earnings growth of 8.5% for 2018. It also delivered positive earnings surprise in each of the trailing four quarters with an average positive surprise of 6.3%. Its long-term projected EPS growth rate is 12%.
Arkema S.A.
France-based Arkema sports a Zacks Rank #2 and a Growth Score of A. The company has expected earnings growth of 8.3% for 2018. The Zacks Consensus Estimate for 2018 for the company have increased by around 1% over the last 60 days. Arkema also has a long-term expected EPS growth rate of 13.1%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.